AU2001258784A1 - Tyrosine phosphatase inhibitors - Google Patents

Tyrosine phosphatase inhibitors

Info

Publication number
AU2001258784A1
AU2001258784A1 AU2001258784A AU5878401A AU2001258784A1 AU 2001258784 A1 AU2001258784 A1 AU 2001258784A1 AU 2001258784 A AU2001258784 A AU 2001258784A AU 5878401 A AU5878401 A AU 5878401A AU 2001258784 A1 AU2001258784 A1 AU 2001258784A1
Authority
AU
Australia
Prior art keywords
tyrosine phosphatase
phosphatase inhibitors
inhibitors
tyrosine
phosphatase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001258784A
Inventor
Nozomi Katayama
Hiroshi Mabuchi
Takahiro Matsumoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU2001258784A1 publication Critical patent/AU2001258784A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001258784A 2000-05-22 2001-05-21 Tyrosine phosphatase inhibitors Abandoned AU2001258784A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000154441 2000-05-22
JP2000-154441 2000-05-22
JP2000-247954 2000-08-10
JP2000247954 2000-08-10
PCT/JP2001/004201 WO2001090067A1 (en) 2000-05-22 2001-05-21 Tyrosine phosphatase inhibitors

Publications (1)

Publication Number Publication Date
AU2001258784A1 true AU2001258784A1 (en) 2001-12-03

Family

ID=26592561

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001258784A Abandoned AU2001258784A1 (en) 2000-05-22 2001-05-21 Tyrosine phosphatase inhibitors

Country Status (5)

Country Link
US (1) US6911468B2 (en)
EP (1) EP1284260A4 (en)
AU (1) AU2001258784A1 (en)
CA (1) CA2410338A1 (en)
WO (1) WO2001090067A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US7220773B2 (en) 2001-04-19 2007-05-22 Dainippon Sumitomo Pharma Co., Ltd. Pyrrole derivative
GB0212785D0 (en) * 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
WO2004018455A1 (en) * 2002-08-23 2004-03-04 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
US20040186151A1 (en) * 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
CA2514363A1 (en) * 2003-02-12 2004-08-26 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
MXPA06000539A (en) * 2003-07-15 2006-03-30 Dainippon Sumitomo Pharma Co Novel heteroaryl derivative.
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
WO2005020913A2 (en) * 2003-08-25 2005-03-10 Combinatorx, Incorporated Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
ZA200605526B (en) * 2004-02-12 2007-11-28 Transtech Pharma Inc Substituted azole derivatives, compositions and methods of use
ATE493973T1 (en) 2004-06-04 2011-01-15 Teva Pharma PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN
EP1803709B1 (en) 2004-09-30 2013-01-02 Takeda Pharmaceutical Company Limited Proton pump inhibitors
EP1837329A4 (en) * 2005-01-14 2009-08-05 Dainippon Sumitomo Pharma Co Novel heteroaryl derivative
WO2006092449A2 (en) * 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
CA2617557A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
EP1919865B1 (en) 2005-08-30 2011-04-06 Takeda Pharmaceutical Company Limited 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
US20070161006A1 (en) * 2006-01-10 2007-07-12 Vita Genomics, Inc. Single nucleotide polymorphisms in protein-tyrosine phosphatase receptor-type delta for the diagnosis of susceptibility to infection and asthma
WO2007089857A2 (en) 2006-01-30 2007-08-09 Transtech Pharma, Inc. Substituted imidazole derivatives and their use as ptpase inhibitors
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
US8969387B2 (en) 2008-08-27 2015-03-03 Takeda Pharmaceutical Company Limited Pyrrole compounds
CN102648183B (en) * 2009-10-07 2015-12-02 卡罗生物股份公司 As the substituted pyrazolecarboxylic of estrogen receptor ligands
US20120225846A1 (en) 2011-03-02 2012-09-06 Bioenergenix Heterocyclic compounds for the inhibition of pask
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
US9073881B2 (en) 2011-09-23 2015-07-07 Hoffmann-La Roche Inc. Benzoic acid derivatives
WO2016074696A1 (en) * 2014-11-10 2016-05-19 Givaudan Ag Perfume ingredients and perfume preparations containing same
GB201706806D0 (en) 2017-04-28 2017-06-14 Sentinel Oncology Ltd Pharmaceutical compounds
CN107935863A (en) * 2017-11-30 2018-04-20 厦门海乐景生化有限公司 The synthetic method of the critical materials compound C of Elagolix

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3168529A (en) * 1962-06-14 1965-02-02 Parke Davis & Co 1-(p-lower alkanoylphenyl)-5-arylpyrrole-2-propionic acid compounds
DK148576A (en) * 1975-04-18 1976-10-19 Boehringer Mannheim Gmbh PHENYLALCANCARBONIC ACID DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
IL92915A0 (en) 1989-01-05 1990-09-17 Ciba Geigy Ag Certain pyrrolylphenyl-substituted hydroxamic acid derivatives
US5096919A (en) * 1989-01-05 1992-03-17 Ciba-Geigy Corporation Pyrrolylphenyl-substituted hydroxamic acid derivatives
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
ATE255090T1 (en) * 1996-08-01 2003-12-15 Merckle Gmbh ACYLPYRROLDICARBONONIC ACIDS AND ACYLINDOLICARBONONIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2
AU2713799A (en) 1998-03-12 1999-09-27 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
ATE228120T1 (en) 1998-05-12 2002-12-15 Wyeth Corp BIPHENYLSULFONYLARYL CARBOXYLIC ACIDS USED FOR TREATING INSULIN RESISTANCE AND HYPERGLYCEMIA
AU4072799A (en) * 1998-05-12 1999-12-13 American Home Products Corporation 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
JP2002514635A (en) 1998-05-12 2002-05-21 アメリカン・ホーム・プロダクツ・コーポレイション Biphenyloxo-acetic acid useful for treating insulin resistance and hyperglycemia
US7314888B1 (en) * 1998-11-05 2008-01-01 Toyama Chemical Co., Ltd. Compounds and medicinal use thereof
US7220773B2 (en) 2001-04-19 2007-05-22 Dainippon Sumitomo Pharma Co., Ltd. Pyrrole derivative

Also Published As

Publication number Publication date
US20030144338A1 (en) 2003-07-31
EP1284260A4 (en) 2004-03-31
EP1284260A1 (en) 2003-02-19
CA2410338A1 (en) 2001-11-29
WO2001090067A1 (en) 2001-11-29
US6911468B2 (en) 2005-06-28

Similar Documents

Publication Publication Date Title
AU2001258784A1 (en) Tyrosine phosphatase inhibitors
AU2001258771A1 (en) -secretase inhibitors
AU2001237041A1 (en) Kinase inhibitors
AUPR392301A0 (en) Protein phosphatase inhibitors
AU2002211663A1 (en) Nf-$g(k)b inhibitors
AU4882101A (en) Mmp-12 inhibitors
AU2002220241A1 (en) Parb inhibitors
AU2002361577A1 (en) Tyrosine kinase inhibitors
AU2001293373A1 (en) 2-guanidino-4-arylchinazolines as NHE-3 inhibitors
AU2002348394A1 (en) Tyrosine kinase inhibitors
AU2001264304A1 (en) Illuminator
AU2002348020A1 (en) Tyrosine kinase inhibitors
AU2001236052A1 (en) Urease inhibitors
AU2001293538A1 (en) Novel protein tyrosine phosphatase inhibitor
AU2002348393A1 (en) Tyrosine kinase inhibitors
AU2001230605A1 (en) Apoptosis inhibitor
AU2001244562A1 (en) Neovascularization inhibitors
AU2002323406A1 (en) Tyrosine kinase inhibitors
AU2002224550A1 (en) Corrosion inhibitors
AU3235100A (en) Prothease inhibitors
AU2002327534A1 (en) Tyrosine kinase inhibitors
AU2001220281A1 (en) Rollerboard for road-skiing
GB0030284D0 (en) Enzyme inhibitors
AU2002222628A1 (en) Keratinocyte proliferation inhibitors
AU2001282234A1 (en) CDC25 phosphatase inhibitors